EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Improving disease‐specific survival for patients with Sezary syndrome in the modern era of systemic therapies

Belinda A Campbell iD, Gabor Dobos iD, Zahra Haider, Martine Bagot iD, Felicity Evison, Carrie van der Weyden iD, Chris McCormack, Caroline Ram-Wolff, Maryam Miladi, H Miles Prince iD, Julia J Scarisbrick iD

British Journal of Haematology · 2024-11 · 205 (5) · 1825-1829

DOI: 10.1111/bjh.19647 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 19.07.2024. Verfasst von Belinda A Campbell und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Sezary Syndrome. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traditionally, Sezary syndrome (SS) has been associated with few therapeutic options and poor prognosis, with 5‐year disease‐specific survival (DSS) less than one‐third in historical cohorts. However, newer therapies and combinations are associated with impressive time‐to‐next‐treatment (TTNT), particularly allogeneic stem‐cell transplantation (AlloSCT) and combination therapies notably those including extracorporeal photopheresis. In this multicentre, international study, we explored the prognostic outcomes of 178 patients exclusively managed for SS, diagnosed between 2012 and 2020, and treated in the modern therapeutic era. In this cohort, 58 different therapies were delivered, with 13.5% of patients receiving AlloSCT. Long‐term survival exceeded historical reports with 5‐year DSS and OS of 56.4% and 53.4% respectively. In those receiving AlloSCT, prognosis was excellent: 5‐year DSS and OS were 90.5% and 78.0% respectively. Confirming the results from the Cutaneous Lymphoma International Consortium (CLIC), LDH and LCT had significant prognostic impact. Unlike earlier studies, stage did not have prognostic impact; we speculate that greater relative benefit favours patients with extensive lymphomatous nodal disease (Stage IVA2) compared to historical reports. For patients ineligible for AlloSCT, the prognosis remains relatively poor (5‐year DSS 51.4% and OS 49.6%), representing ongoing unmet needs for more effective novel agents and investigation of improved therapeutic combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sezary SyndromeHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overHematopoietic Stem Cell TransplantationPrognosisSurvival RateCombined Modality TherapyDisease-Free SurvivalPhotopheresisSkin Neoplasms

Stichwörter der Autor:innen

Sezary syndromecutaneous T‐cell lymphomaprognosisprognostic factorssurvival

Autor:innen und Institutionen

  • Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • Department of Clinical Pathology, University of Melbourne, Parkville, Victoria, Australia.
  • Department of Dermatology, Hôpital Saint Louis, Université Paris Cité, Paris, France.
  • Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
  • Beckenham Beacon, Kings College Hospitals NHS Foundation Trust, London, UK.

ORCID-Profile: Belinda A Campbell, Gabor Dobos, Martine Bagot, Carrie van der Weyden, H Miles Prince, Julia J Scarisbrick

Zitieren

APA

Campbell, B. A., Dobos, G., Haider, Z., Bagot, M., Evison, F., van der Weyden, C., McCormack, C., Ram-Wolff, C., Miladi, M., Prince, H. M., & Scarisbrick, J. J. (2024). Improving disease‐specific survival for patients with Sezary syndrome in the modern era of systemic therapies. British Journal of Haematology, 205(5), 1825-1829. https://doi.org/10.1111/bjh.19647

Vancouver

Campbell BA, Dobos G, Haider Z, Bagot M, Evison F, van der Weyden C, et al. Improving disease‐specific survival for patients with Sezary syndrome in the modern era of systemic therapies. British Journal of Haematology. 2024;205(5):1825-1829. doi:10.1111/bjh.19647

BibTeX
@article{Campbell2024,
  author = {Campbell, Belinda A and Dobos, Gabor and Haider, Zahra and Bagot, Martine and Evison, Felicity and van der Weyden, Carrie and McCormack, Chris and Ram-Wolff, Caroline and Miladi, Maryam and Prince, H Miles and Scarisbrick, Julia J},
  title = {Improving disease‐specific survival for patients with Sezary syndrome in the modern era of systemic therapies},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {205},
  number = {5},
  pages = {1825--1829},
  doi = {10.1111/bjh.19647}
}
Kostenlos starten →